The real issue is not whether Medicines Australia actually constructs the CRS but whether the ACCC accepts it has used "reasonable endeavours" and that the "significant unanticipated issues" could not be overcome. …
Latest Video
New Stories
-
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News -
R&D tax shake up risks sending Australia’s biotech talent and jobs overseas
June 9, 2026 - - Latest News -
It was an unintentionally revealing discussion about the history and reality of agreements
June 9, 2026 - - Latest News -
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News -
Rare Cancers Australia co-founder Kate Vines recognised in King's Birthday Honours
June 8, 2026 - - Latest News